Quantification of matrix metalloproteinase activity in plasma of patients enrolled in a BAY 12-9566 phase I study

International Journal of Cancer

Volumn 91, Issue 6, 2001, Pages 857-862

  Duivenvoorden, Wilhelmina C M ^a   Hirte, Holger W ^a   Singh, Gurmit ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

BAY 12 9566; Inhibitors; Matrix metalloproteinase; Plasma

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STROMELYSIN; TANOMASTAT;

ADULT; ARTICLE; CANCER RESEARCH; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ACTIVITY; ENZYME ACTIVITY; FEMALE; FLUOROMETRY; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SOLID TUMOR; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEOPLASMS; ORGANIC CHEMICALS;

EID: 0035869702     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1135>3.0.CO;2-M     Document Type: Article

References (75)

1. Changing views of the role of matrix metalloproteinase in metastasis
2. Proteases as prognostic markers in cancer
3. Complex roles of matrix metalloproteinase in tumor progression
4. Activity of type IV collagenases in benign and malignant breast disease
5. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
6. Type IV collagenase (M, 72,000) expression in human prostate: Benign and malignant tissue
7. Immunohistochemical analysis of type IV collagenase expression in prostatic hyperplasia and adenocarcinoma
8. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia
9. Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary
10. Expression of 72 kDa type IV collagenase (gelatinase A) in benign and malignant ovarian tumors
11. Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form
12. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues
13. Increased expression of the M, 72,000 type IV collagenase in human colonic adenocarcinoma
14. Levels of matrix metalloproteinase in bladder cancer correlate with tumor grade and invasion
15. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix. Clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
16. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential
17. Distribution of collagenase and tissue inhibitor of metalloproteinase (TIMP) in colorectal tumors
18. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors
19. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
20. Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumors
21. Matrix metalloproteinase-1 and -3 in breast cancer: Correlation with progesterone receptors and other clinicopathologic features
22. Expression of tissue inhibitor of metalloproteinase TIMP-2 in human colorectal cancer: A predictor of tumour stage
23. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive squamous cell carcinomas
24. Distribution of stromelysin-3 mRNA transcripts and microvessels in human breast carcinoma
25. High levels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma
26. Expression of metalloproteinase genes in human prostate cancer
27. Expression and tissue localization of membrane-types 1,2 and 3 matrix metalloproteinase in human invasive breast cancer carcinomas
28. Enhanced production and activation of progelatinase A mediated by membrane type 1 matrix metalloproteinase in human papillary thyroid carcinomas
29. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP): MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis
30. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas
31. Analysis of MT1-MMP and MMP-2 expression in human gastric cancers
32. Membrane-type matrix metalloprotainase-1 (MT1-MMP) gene is overexpressed in highly invasive hepatocellular carcinomas
33. Increased expression of membrane type 1 matrix metalloproteinase and matrix metalloproteinase-2 with tumor dedifferentiation in hepatocellular carcinomas
34. Small molecular weight beta 1 serum protein which specifically inhibits human collagenases
35. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
36. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models
37. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
38. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice
39. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor Batimastat (BB94)
40. Batimastat, a synthetic inhibitor of matrix metalloproteinase, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
41. Activity of the biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in murine in vivo models
42. Inhibition of human breast cancer regrowth and pulmonary metastases by BAY 12-9566 in athymic mice
43. Anti-metastatic activity of BAY 12-9566 in a human colon carcinoma HCT116 orthotopic model
44. Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinase
45. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
46. Broad antitumor and antiangiogenic activities af AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
47. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis
48. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjörgen's syndrome contain increased latent and active gelatinase-B levels
49. Serum levels of collagenase, stromelysin-1, and TIMP-1
50. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-I in sera from patients with rheumatoid arthritis
51. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumors
52. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade
53. Urinary type IV collagenase: Elevated levels are associated with bladder transitional cell carcinoma
54. Serum metalloproteinase and their inhibitors: Markers for malignant potential
55. Matrix metalloproteinases-1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer
56. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy
57. Elevated levels of serum and plasma metalloproteinase in patients with gastric cancer
58. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor of matrix metalloproteinase-2 in patients with liver disease
59. 72-Kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors of the ovary: A clinicopathological, immunohistochemical, and serological study
60. Type IV collagenase/gelatinase (MMP-2) is not increased in plasma of patients with cancer
61. Plasma assay of gelatinase B: Tissue inhibitor of metalloproteinase complexes in cancer
62. Elevated plasma levels of matrix metalloproteinase-9 (92 kd type IV collagenase/gelatinase B) in hepatocellular carcinoma
63. Elevated levels of circulating plasma matrix metalloproteinase 9 levels in non-small cell lung cancer patients
64. Matrix metalloproteinase and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
65. Association between plasma MMP-9 activity and the outcome of breast cancer patients
66. Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
67. BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties
68. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates
69. Human neutrophil gelatinase: A marker for circulating neutrophils. Purification and quantification by enzyme linked immunosorbent assay
70. Matrix metalloproteinase in immunity
71. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 9 using monoclonal antibodies
72. Analytical aspects regarding the measurements of metalloproteinase and their inhibitors in blood
73. Biochemical characterization of the catalytic domain of human matrix metalloproteinase 19. Evidence for a role as a potent basement membrane degrading enzyme
74. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity
75. Metalloproteinase and tissue inhibitors of metalloproteinase